SCHEMBL15217048

SCHEMBL15217048

CC(C)(C)OC(=O)NN(CC1CC(F)(F)C1)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 3/20 0.39
CNR2 P34972 1/20 0.38
KMT2A Q03164 4/20 0.33
MEN1 O00255 2/20 0.33
MAPK1 P28482 1/20 0.33
CA14 Q9ULX7 2/20 0.33
APLNR P35414 2/20 0.33
TDP1 Q9NUW8 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CA1 P00915 2/20 0.31
CA7 P43166 2/20 0.31
CA2 P00918 1/20 0.31
CTSD P07339 1/20 0.31
CTSL P07711 1/20 0.31
CTSB P07858 1/20 0.31
CTSS P25774 1/20 0.31
HDAC1 Q13547 2/20 0.31
HDAC4 P56524 1/20 0.31
GAA P10253 1/20 0.31
EPHX1 P07099 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15103109 0.86 CNR2 (0.41) AKT1CNR2KMT2ACA14APLNR
SCHEMBL283318 0.84 CNR2 (0.49) AKT1CNR2KMT2AMEN1CA14
SCHEMBL482800 0.81 CNR2 (0.45) AKT1CNR2KMT2ATDP1ALDH1A1
SCHEMBL13449911 0.80 CNR2 (0.44) AKT1CNR2KMT2AALDH1A1CTSL
SCHEMBL15217046 0.78 CNR2 (0.38) AKT1CNR2KMT2AMEN1MAPK1
SCHEMBL27839853 0.71 AKT1 (0.48) AKT1KMT2AMEN1CA14APLNR
SCHEMBL17706185 0.70 AKT1 (0.45) AKT1CNR2APLNRCTSDCTSL
SCHEMBL283816 0.70 LMNA (0.38) CNR2KMT2AMEN1GAA
SCHEMBL283815 0.70 LMNA (0.38) CNR2KMT2AMEN1GAA
SCHEMBL9548234 0.70 CA14 (0.44) AKT1KMT2AMEN1CA14APLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822448-B2 Pyrazoloquinoline compound ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-8822448-B2 Pyrazoloquinoline compound ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-20130225553-A1 PYRAZOLOQUINOLINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-08-29 US disclosed
US-20130225553-A1 PYRAZOLOQUINOLINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225553-A1 PYRAZOLOQUINOLINE COMPOUND PDE9A, PDE5A, PDE2A AKT1 2740/4885CNR2 4313/4885KMT2A 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.